Cancer-associated mutations of SPOP play diverse roles based on the substrate and context: prostate cancer-associated SPOP mutations reduce degradation of BET proteins and may increase resistance to BET inhibitors22,26, whereas endometrial cancer-associated SPOP mutants increase degradation of BET proteins and may sensitize cells to BET inhibitors43. This evidence concerns the gene SPOP and prostate cancer.